Collagen Solutions in line for â‚¬500,000 EU injection

Collagen Solutions is set to take part in a second EU-funded research project. Picture: Contributed

This article contains affiliate links. We may earn a small commission on items purchased through this article, but that does not affect our editorial judgement.

Life sciences firm Collagen Solutions has been invited to take part in a scheme, funded by the European Union, aimed at meeting a 'pressing' clinical need for cell-based tissue regeneration techniques.

The Glasgow-based company, which develops collagen components for use in regenerative medicine and medical devices, will receive about €500,000 (£425,000) of EU cash for the five-year Horizon 2020 project, which is expected to kick off early next year.

Mike Mitchell, analyst at house broker Panmure Gordon, said: “We consider this to be a further validation of the company’s core competencies in collagen-based biomaterials with application in advanced regenerative medicine therapies. Grant funding is an excellent source of monies for small, technology-focused businesses and Collagen Solution’s repeated success in this field is notable.”

Aim-quoted Collagen Solutions is already a partner on an existing €4 million Horizon 2020 programme tasked with developing collagen formulations for the treatment of Parkinson’s Disease.

Collagen Solutions wins Parkinson’s disease role

Chief executive Jamal Rushdy said: “Our selection as an industrial collaborator in a second Horizon 2020 project recognises the leadership position of Collagen Solutions in researching, developing and providing unique collagen-based biomaterials used in advanced regenerative medicine therapies. Our participation further enhances our scientific expertise in these areas, which also provides greater value to the development partners we serve.”

Click here to ‘Like’ The Scotsman Business on Facebook